Board of Directors



Shareholder Tools


Dr. Bernstein has served on Achaogen’s board of directors since July 2017. From 1992 to 2015, Dr. Bernstein was the Chairman and Editor-in-Chief of BioCentury where she wrote and published on biotechnology developments. Dr. Bernstein has received numerous awards for her contributions to the biotechnology industry including being named one of The WorldVIEW 100 most influential people in biotech today by Scientific American (2015) and receiving a Special Recognition award at the American Liver Foundation's Salute to Excellence, honoring individuals who have made an outstanding contribution to biotechnology and medical innovation (2007). Dr. Bernstein served for many years as a member of the Brandeis University Science Advisory Council. She is on the board of trustees of the Keck Graduate Institute (KGI) of the Applied Life Sciences and is a member of the board of advisors of KGI's School of Pharmacy. Dr. Bernstein is also a director at Ovid Therapeutics Inc., which is focused on developing drugs for orphan diseases of the brain. From September 2015 to October 2016, she served on the board of directors of Vitae Pharmaceuticals Inc., which was acquired by Allergan plc.
 
Dr. Bernstein holds a Ph.D. in political science from Stanford University and a B.A. in politics and history from Brandeis University.

Mr. Doyle has served as a member of Achaogen’s board of directors since November 2012. Mr. Doyle joined Castlight Health, a healthcare information company, as Chief Financial Officer in November 2012, and leads the finance, human resources, legal, and corporate development teams. Previously, Mr. Doyle served as Achaogen’s Chief Operating Officer from August 2009 to November 2009 and from February 2011 to November 2012, and as its Chief Financial Officer from November 2009 to February 2011. At Achaogen, Mr. Doyle managed business development, corporate finance, information technology, and business strategy. Prior to joining Achaogen, Mr. Doyle was Vice President of Finance and Corporate Planning at Genentech, Inc., from 2007 to 2009. Mr. Doyle is a member of the 2012 class of Henry Crown Fellows at the Aspen Institute. He has a B.S. in Business Administration from California Polytechnic State University, San Luis Obispo and an M.B.A. from the University of California, Berkeley.

Dr. Fischbach has served on Achaogen’s board of directors since November 2015.  Since May 2015, Dr. Fischbach has served as an Associate Professor in the Department of Bioengineering and Therapeutic Sciences at UCSF, and from 2009 to May 2015, Dr. Fischbach served as an Assistant Professor at UCSF. Prior to joining UCSF, Dr. Fischbach spent two years as an independent fellow at Massachusetts General Hospital. He is a member of the California Institute for Quantitative Biosciences (QB3).  Dr. Fischbach is also the recipient of multiple awards, including the NIH Director's New Innovator Award, a Fellowship for Science and Engineering from the David and Lucille Packard Foundation, a Medical Research Award from the W.M. Keck Foundation, a Burroughs Wellcome Fund Investigators in the Pathogenesis of Infectious Disease award, a Glenn Award for Research in Biological Mechanisms of Aging, and the Young Investigator Grant for Probiotics Research from the Global Probiotics Council. Dr. Fischbach received his A.B. in Biochemistry and Ph.D. in chemistry from Harvard in 2007.

Ms. Gilbert has served on Achaogen’s board of directors since January 2017.  In 2008, Ms. Gilbert became a founding member of the Ironwood Pharmaceutical legal department, providing leadership and oversight and establishing the company’s compliance function as Ironwood grew from a privately-held, research-based organization to a publicly-traded, fully-integrated commercial biotechnology company. Ms. Gilbert brings significant strategic leadership and two decades of experience navigating biopharmaceutical companies through transformational change, as well as expertise in corporate transactions, corporate governance, employment law and legal and operational issues relevant to launching new medicines into specialty and primary care markets. Prior to joining Ironwood, Ms. Gilbert was Vice President, Deputy General Counsel at Cubist Pharmaceuticals, Inc. from 2002 to 2008, where she supported the launch of Cubist’s first acute care antibiotic, and she served as Corporate Counsel at Genzyme Corp. from 1999 to 2001. Halley began her career at Skadden, Arps, Slate, Meagher & Flom LLP, where she specialized in mergers and acquisitions and securities law. She holds a J.D. from Northwestern University School of Law and a B.A. from Tufts University.

Kenneth J. Hillan M.B. Ch.B.
Dr. Hillan joined Achaogen in 2011 as Chief Medical Officer and was appointed Chief Executive Officer and a member of its board of directors in October 2011. Prior to joining Achaogen, from August 1994 to April 2011, Dr. Hillan served at Genentech, Inc. (acquired by Roche in 2009), a pharmaceutical company. Dr. Hillan was responsible for numerous successful drug approvals and led the medical and scientific strategies for its Immunology, Tissue Growth and Repair drug portfolio. He served in a number of key leadership positions in research and development, including Senior Vice President Clinical Development, Inflammation, Vice President Immunology, Tissue Growth and Repair (ITGR), Vice President Development Sciences and Vice President Research Operations and Pathology. Dr. Hillan also previously served as Senior Vice President and head of Clinical Development and Product Development Strategy in Asia-Pacific for Roche in Shanghai, China. Dr. Hillan currently serves on the board of directors of Zymeworks, Inc., and he served on the board of directors of Relypsa, Inc. from 2014 until 2016, when it was acquired by Galenica AG.
 
Dr. Hillan has an M.B. Ch.B. (Bachelor of Medicine and Surgery) degree from the Faculty of Medicine at the University of Glasgow, U.K. Dr. Hillan is a Fellow of the Royal College of Surgeons (FRCS), and a Fellow of the Royal College of Pathologists (FRCPath). Dr. Hillan has authored dozens of scientific publications and is a named inventor on almost 50 issued patents.

Dr. Lieginger has served on Achaogen’s board of directors since March 2015.  Dr. Lieginger has most recently served as Senior Vice President, Managed Care and Customer Operations at Genentech, Inc. from 2004 to July 2014, as well as Director of the Genentech Foundation from 2010 to 2012. He originally joined Genentech as Vice President, Managed Care and Customer Operations in 2004 and served as a member of Genentech’s Commercial Leadership Committee. Prior to joining Genentech, Dr. Lieginger was Vice President, National Insurer and Employer Segment (Managed Markets Division) at GlaxoSmithKline plc, where he also led teams in U.S. and global business development, finance, strategic contracting, manufacturing, marketing, and sales. He completed his residency in clinical pharmacy at the University of California in San Francisco, served for four years as Assistant Clinical Professor of Medicine at the University of California, Davis School of Medicine, and has served on the Board of Trustees at University of the Sciences in Philadelphia since 2013.

Dr. Roberts has served on Achaogen’s board of directors since August 2004, and he has served as our Chairman since December 2009. Dr. Roberts joined Venrock, a venture capital investment firm, in 1997, where he serves as Partner. From 1989 to 1992, Dr. Roberts worked in the corporate finance department of Kidder, Peabody & Co., a brokerage company. Dr. Roberts is currently on the board of directors of three publicly traded companies: Zeltiq Aesthetics, Castlight Health, and Vitae Pharmaceuticals, Inc. He also serves on the board of directors of several private companies and previously served on the board of directors of publicly traded Athenahealth, Inc., XenoPort, Inc., and Sirna Therapeutics, Inc. He has a B.A. in Chemistry from Dartmouth College and a Ph.D. in chemistry and chemical biology from Harvard University.

Mr. Smither has served on our board of directors since December 2013. Mr. Smither served as Chief Financial Officer of Kythera Biopharmaceuticals, Inc. from November 2007 until it was acquired by Allergan in October, 2015 for $2.1 billion.  As CFO of Kythera, he was responsible for finance during multiple private and public capital raising rounds including the Company’s IPO and subsequent follow-on offerings, licensing and repurchasing of the international rights of its lead product to Bayer, and placement of several venture debt facilities.
 
From 1998 to 2007, Mr. Smither held various positions at Amgen. From 2001 to 2004, Mr. Smither served as Vice President of Finance and Administration of Amgen’s European Division, where he was responsible for financial operations in 28 European countries. Prior to that role, Mr. Smither served as Head of Internal Audit, and following his time in Europe was Executive Director of Corporate Accounting at Amgen. 
 
Prior to joining Amgen, Mr. Smither served as Audit Partner at Ernst & Young LLP, a public accounting firm, and following his time at Ernst & Young had served as the Chief Financial Officer of several early stage companies. 
 
Mr. Smither received a B.S. in Business Administration from California State University, Los Angeles. Mr. Smither is a Certified Public Accountant (inactive) and a member of the American Institute of Certified Public Accountants, the California Society of Certified Public Accountants and Financial Executives International.
 

 

Mr. Stea has served on our board of directors since June 2015. Mr. Stea recently retired from Cubist Pharmaceuticals where he served as Senior Vice President of Commercial Operations from 2009 to February 2015, leading all commercial operations, including the launch and sales of Cubicin, Zerbaxa, and Sivextro.  Prior to this, Mr. Stea served as Cubist’s Vice President, Sales and Marketing from 2007 to 2009.  As a member of the Cubist Business Operations team, Mr. Stea led the growth of Cubicin to unprecedented revenues for an acute care antibiotic, and most recently led the launches of Sivextro and Zerbaxa.  Having joined Cubist as an original member of the commercial organization, Mr. Stea served as Cubist Vice President of Sales from 2005 to 2007, Executive Director of Sales from 2002 to 2005, and as a member of the Cubist Operating Committee from 2009 to February 2015, which was responsible for resource allocation, company strategy, risk management, and compliance, among other things. Mr. Stea previously held leadership positions at Amgen from 1988 to 1997, where he was the first employee of its sales organization, responsible for the launch of Epogen and Neupogen.  Mr. Stea holds a Bachelor’s Degree in Business Administration from Temple University and completed the University of Michigan’s executive program as well as Harvard Business School’s program in leadership and strategy in pharmaceuticals and biotechnology.